ADCT 402

Drug Profile

ADCT 402

Alternative Names: ADCT-402

Latest Information Update: 13 Feb 2016

Price : $50

At a glance

  • Originator ADC Therapeutics
  • Class Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute lymphoblastic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 09 Feb 2016 Phase-Ia clinical trials in Acute lymphoblastic leukaemia (Second-line therapy or greater) in USA (IV) (NCT02669264)
  • 09 Feb 2016 Phase-Ia clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV)
  • 05 Dec 2015 Pharmacodynamics and adverse events data from preclinical studies in Haematological cancers presented at the 57th Annual Meeting of the American Society of Haematology (ASH-Hem,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top